Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

DRUG REVIEW
[View FULLTEXT] [Download PDF
 
Year : 2013  |  Volume : 59  |  Issue : 1  |  Page : 48-50  

Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma

AK Dubey1, S Dubey2, SS Handu1, MA Qazi1 
1 Department of Pharmacology, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India
2 Department of Pathology, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India

Correspondence Address:
A K Dubey
Department of Pharmacology, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh
India

Treatment of basal cell carcinoma (BCC) usually involves surgical interventions and laser ablation, but in locally advanced BCC, which arise either from earlier untreated lesions or from recurrence of aggressive BCC, surgery and radiotherapy are not helpful. Vismodegib, the first oral-targeted therapy for locally advanced and metastatic BCC, unsuitable for surgery or radiotherapy, was recently approved by US Food and Drug Administration (FDA). The drug was under the priority review program of FDA and was approved on the basis of promising results of phase II trial. Vismodegib acts by targeting the hedgehog pathway, which is activated abnormally in most BCCs. Approval of vismodegib is a big step ahead in the treatment of advanced BCC, where there was no other effective drug therapy till now.


How to cite this article:
Dubey A K, Dubey S, Handu S S, Qazi M A. Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma.J Postgrad Med 2013;59:48-50


How to cite this URL:
Dubey A K, Dubey S, Handu S S, Qazi M A. Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma. J Postgrad Med [serial online] 2013 [cited 2020 Aug 4 ];59:48-50
Available from: http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2013;volume=59;issue=1;spage=48;epage=50;aulast=Dubey;type=0


 
Tuesday, August 4, 2020
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer